Selective non-ATP competitive inhibitor of GSK 3β (IC50 = 2 μM); thiadiazolidinone deriviative. Does not inhibit Cdk-1/cyclin B, CK-II, PKA or PKC at >100 μM. Reduces severity of L-dopa-induced dyskinesia in a Parkinson's disease in vivo model.
|Storage||Store at -20°C|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions
The following data is based on the product molecular weight 222.26. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||4.5 mL||22.5 mL||44.99 mL|
|5 mM||0.9 mL||4.5 mL||9 mL|
|10 mM||0.45 mL||2.25 mL||4.5 mL|
|50 mM||0.09 mL||0.45 mL||0.9 mL|
References are publications that support the products' biological activity.
Xie et al (2016) Inhibition of Glycogen Synthase Kinase-3β (GSK-3 beta ) as potent therapeutic strategy to ameliorates L-dopa-induced dyskinesia in 6-OHDA parkinsonian rats. Sci.Rep. 6 23527 PMID: 26997328
Martinez et al (2002) First non-ATP competitive glycogen synthase kinase 3 beta (GSK-3beta) inhibitors: thiadiazolidinones (TDZD) as potential drugs for the treatment of Alzheimer's disease. J.Med.Chem. 45 1292 PMID: 11881998
If you know of a relevant reference for TDZD 8, please let us know.
View Related Products by Target
View Related Products by Product Action
Keywords: TDZD 8, supplier, TDZD8, NP01139, NP_01139, Selective, non-ATP, competitive, inhibitor, GSK, 3, β, L-dopa-induced, dyskinesia, NP, 01139, Glycogen, Synthase, Kinase, 3, Glycogen, Synthase, Kinase, Glycogen, Synthase, Kinase, 3, Tocris Bioscience
Citations for TDZD 8
Citations are publications that use Tocris products.
Currently there are no citations for TDZD 8. Do you know of a great paper that uses TDZD 8 from Tocris? If so please let us know.
TDZD 8 Reviews
Average Rating:(Based on 0 Reviews)
Literature in this Area
Alzheimer's disease (AD) is a degenerative brain disease and the most common cause of dementia, affecting approximately 47 million people worldwide. Updated in 2015, this poster summarizes the structural and functional changes observed in the progression of this neurodegenerative disease, as well as classic AD drug targets.
Schizophrenia is a debilitating psychiatric disorder that affects 1% of the worldwide population. This poster describes the neurobiology of Schizophrenia, as well as highlighting the genetic and environmental factors that play a fundamental role in the etiology of the disease. The current and emerging drug targets are also discussed.